MALVERN, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference.
Conference Dates: Tuesday, December 1 to Thursday, December 3, 2020.
A link to the fireside chat presentation is available on the “Investors” section of the Company’s website at ir.telabio.com.
About TELA Bio, Inc.
TELA Bio, Inc. is a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA’s products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA’s portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.
TELA Bio Contact
Stuart Henderson
Vice President, Corporate Development and Investor Relations
TELA Bio, Inc.
484-320-2930
Investor Contact
Greg Chodaczek
347-620-7010
ir@telabio.com
(Now your health can be as cutting-edge as your wallet in 2025.) PORTLAND, Ore., Jan.…
AUSTIN, Texas, Jan. 1, 2025 /PRNewswire/ -- re:3D, Inc. is pleased to announce the winner…
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize…
Provides financial flexibility by reducing near-term debt maturities, deferring principal redemption payment, and reducing near-term…
Innovative Solutions Transform Treatment for Burn Victims, Chronic Wounds, and Scar ReductionCHICAGO, Dec. 31, 2024…
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…